Contract development and manufacturing organization (CDMO) Saneca Pharma is investing heavily in its active pharmaceutical ingredients (API) capabilities to support client demand for smaller batch sizes and streamlined scale-up.
The Slovakia-based company is strengthening its infrastructure and expanding its suite of equipment within its five API production units to reinforce its expertise in opiate and synthetic drug development and production.
This investment includes several smaller reactors that enable Saneca Pharma to now deal with batches from around 1 to 30 kg in its new kilo lab. This lab then allows for scale-up and optimisation activities that simulate the CDMO’s large scale production processes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze